Tofersen: A Novel Option for the Treatment of Amyotrophic Lateral Sclerosis

Tofersen provides a promising targeted treatment option for pathogenic SOD1 ALS. Ongoing studies will clarify its long-term clinical impact.

Authors

Institutions

Publication Details

Journal
Annals of Pharmacotherapy
Published
2026-02-04
DOI
https://doi.org/10.1177/10600280251408862
Primary Topic
Amyotrophic Lateral Sclerosis Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Tofersen: A Novel Option for the Treatment of Amyotrophic Lateral Sclerosis

Anna Nogid, Michael Karros, Marissa DiFulco
Annals of Pharmacotherapy
Amyotrophic Lateral Sclerosis Research
article

Tofersen: A Novel Option for the Treatment of Amyotrophic Lateral Sclerosis

Anna Nogid, Michael Karros, Marissa DiFulco
article en

Abstract

Tofersen provides a promising targeted treatment option for pathogenic SOD1 ALS. Ongoing studies will clarify its long-term clinical impact.

Annals of Pharmacotherapy
Fairleigh Dickinson University (US)
Openalex Percentile: Top 67%
Amyotrophic Lateral Sclerosis Research
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Tofersen: A Novel Option for the Treatment of Amyotrophic Lateral Sclerosis — Anna Nogid, Michael Karros, et al. · Annals of Pharmacotherapy (2026) | TGRS Research Map | TGRS